Fei Wang | Tumor immunology | Best Researcher Award 

Dr. Fei Wang | Tumor immunology | Best Researcher Award 

Institute of Biological and Medical Imaging (IBMI) | Germany

AUTHOR PROFILE

EARLY ACADEMIC PURSUITS

Dr. Fei Wang’s academic journey began at Zunyi Medical University, where she completed her Bachelor Degree in Clinical Medicine in June 2014. Her pursuit of specialization continued with a Master’s Degree in Oncology from the same institution, which she completed in June 2017. Her foundational education laid the groundwork for her subsequent focus on tumor immunology and cancer research.

PROFESSIONAL ENDEAVORS

Dr. Wang's professional experience spans several key roles in medical and research settings. She is currently a Postdoctoral Fellow at the Institute of Biological and Medical Imaging (IBMI), Helmholtz Center Munich, since February 2024. In this role, she is researching the relationship between anti-tumor therapy and the tumor microenvironment and is also the Principal Investigator (PI) of an institute seed fund project. Prior to this, Dr. Wang was a Doctoral Candidate at the Radiation-Immuno Oncology Project Group, TranslaTUM, Klinikum rechts der Isar, Technical University of Munich, where she conducted preclinical research on various tumor models and completed her doctoral defense with the highest honors ("SUMMA CUM LAUDE"). Her earlier experience includes working as a Physician at Zunyi Medical University Hospital, where she managed clinical trials and conducted research on drug resistance in lung cancer.

CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Wang's research focus is prominently on tumor immunology and the mechanisms of anti-tumor drugs. As a Postdoctoral Fellow, she is investigating how anti-tumor therapies interact with the tumor microenvironment, contributing to a deeper understanding of cancer treatment mechanisms. Her doctoral research involved exploring new anti-tumor drugs, identifying potential targets, and studying the role of the immune system in tumor therapy. She has worked on various tumor models including colorectal cancer, glioma, lung cancer, and breast cancer, with a focus on preclinical research that informs clinical practice. Dr. Wang has been involved in multiple projects funded by German natural science funds, as well as several National Natural Science Foundation and provincial science fund projects from China, highlighting her significant contributions to the field.

IMPACT AND INFLUENCE

Dr. Wang’s work in tumor immunology and cancer research has had a notable impact on the field. Her research has contributed to advancements in understanding the tumor microenvironment and the mechanisms of anti-tumor drugs. Her role as a PI for various projects underscores her leadership in advancing research on precise cancer treatments. The findings from her research have potential implications for improving cancer therapies and patient outcomes. Her publication record, including several first-author and corresponding author SCI papers, reflects her influence and contribution to the scientific community.

ACADEMIC CITATIONS

Dr. Wang’s research in tumor immunology and cancer therapy has been cited in numerous academic publications, highlighting the significance of her work in the field. Her contributions to understanding anti-tumor drug mechanisms and the tumor microenvironment are recognized in the literature, reinforcing her role in advancing cancer research.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Wang's legacy in tumor immunology is marked by her significant contributions to understanding cancer treatment mechanisms and her role in advancing research through various funded projects. Her future contributions are likely to further enhance the field of cancer research, particularly in developing new therapeutic strategies and improving patient outcomes. Her ongoing research will continue to impact the understanding of tumor microenvironments and anti-tumor therapies, shaping the future of cancer treatment and research.

TUMOR IMMUNOLOGY 

Dr. Wang’s research prominently features tumor immunology, focusing on the interactions between anti-tumor therapies and the tumor microenvironment. Her investigations into the mechanisms of anti-tumor drugs contribute to the broader understanding of tumor immunology and its implications for cancer treatment. As she continues her work, her contributions to tumor immunology will be crucial in advancing therapeutic approaches and improving clinical outcomes.

NOTABLE PUBLICATION